RecruitingPhase 1Phase 2NCT04685226
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
A Multicenter, Nonrandomized, Open-Label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Solid Tumors
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Enrollment
310 participants
Start Date
Sep 27, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors
Eligibility
Min Age: 12 Years
Inclusion Criteria9
- Histopathologically confirmed surgically unresectable locally advanced or metastatic solid tumors or primary central nervous system (CNS) tumors..
- Age:
- Adult Cohort: Age ≥ 18 years; Adolescent cohort: 12 ≤ years < 18 years.
- At least one measurable lesion as per RECIST1.1 criteria, or for primary CNS tumors, at least one measurable lesion as per RANO or INRC criteria.
- Adult cohort: ECOG PS score of 0-1;
- Adolescent cohort: Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) PS score > 60.
- Life expectancy > 3 months.
- Female patients or male patients of childbearing potential, who agree to use medically acceptable effective methods of birth control throughout the study up to 12 weeks after the last dose of the study treatment.
- Patients who have signed the Informed Consent Form voluntarily and agree to follow the therapeutic regimen and the visit schedule.
Exclusion Criteria5
- Any other active malignancy within 5 years prior to the first dose of the study drug.
- Prior anti-cancer treatment within 28 days prior to the first dose.
- Major surgical procedures within 4 weeks or minor surgical procedures within 2 weeks prior to the first dose of the study drug.
- A history of allergic disease, severe drug allergy, known hypersensitivity to any component of the ICP-723 tablet formulation.
- Other situations that, in the investigator's opinion, would make the subject unsuitable for participation in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGICP-723
ICP-723 is a white, round, uncoated table
Locations(24)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04685226
Related Trials
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
NCT033661161 location
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT0553614125 locations
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT0671013281 locations
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT045704235 locations
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873779 locations